The present invention relates to a process for preparing sulfide compounds from aryl halogen compounds having various electron-donating, electron-withdrawing or hydrogen-donating substituents via one-step reaction, and the sulfide derivatives prepared therefrom. More specifically, the invention relates to a process for preparing various alkyl aryl sulfides represented by Formula (III) which have important roles in syntheses of organic chemistry and medicinal chemistry, via one-step reaction.
Alkyl aryl sulfide compounds represented by Formula (III) have very wide utility spectrum in organic chemistry and medicinal chemistry. Thus, a variety of processes for preparing such sulfide compounds have been developed by many researchers. Among the processes, a synthetic process wherein a compound of Formula (I) is reacted with an organic compound containing alkyl or arylthio alcohol and halogen in the presence of a strong base is the most generalized process (Synthesis 1972, 101, 1977, 357, Chemical Reviews 1978, 78, 363). As another synthetic process, there is a carbon-sulfur bonding reaction using palladium (Pd) or copper (Cu) catalyst, as shown in Reaction Scheme (2) (J. Am. Chem. Soc., 1995, 117, 11598, J. Org. Chem. 1998, 63, 9606, 2001, 66, 8677, Aus. J. Chem. 1985, 38, 899, Org. Lett. 2000, 2, 2019, 2002, 4, 2803). In addition, a synthetic process of a sulfide was patented as an important stage in synthesis of GW501516 which has been known as a therapeutic agent for hypertension and hypercholesterolemia, and cardiac disorders caused by such diseases, as shown in Reaction Scheme (3) and (4) (PCT Laid-open Publication WO 01/00603 A1).
In spite of having a lot of utilities, sulfide derivatives have following deficiencies in their process for preparation:
Thus, a method to rapidly prepare an alkyl aryl sulfide with simple and low-costed process has been required.
It is the object of the present invention to provide a process for preparing alkyl aryl sulfides of Chemical Formula (III) via one-step reaction without separation or purification of an intermediate compound, from low-priced and various aryl halogen compounds in a short reaction time with high yield.
As considering the situation described above, the present inventors performed intensive studies on this matter and found that an alkyl aryl sulfide of Chemical Formula (III) is obtained by substituting a halogen from an aryl halogen compound with alkyl lithium organometallic reagent when the compound of Chemical Formula (I) has an electron-donating or an electron-withdrawing substituent, and continuously reacting with the compound of Chemical Formula (II) and sulfur; or by reacting the aryl halogen compound of Chemical Formula (I) containing a hydrogen-donating substituent (—OH, —NH2, —NRH, —COOH) with an alkylmagnesium halide (Grignard reagent) to protect the hydrogen-donating substituent; substituting the halogen with alkyl lithium organometallic reagent, and continuously reacting with the compound of Chemical Formula (II) and sulfur, to complete the invention.
wherein, A represents CH or a nitrogen atom,
X1 represents a halogen atom,
X2 represents a halogen atom or a leaving group,
X3 represents a halogen atom,
R1 represents a hydrogen atom, a halogen atom, a C1-C7 alkyl group, a C1-C7 alkyloxy group, a C1-C7 alkylthiooxy group, an aryl group, a hydroxyl group, a hydroxymethyl group, a hydroxyethyl group, an amine group, an aminomethyl group, an aminoethyl group, an alkylamine group, a dialkylamine group or a carboxy group, wherein the alkyl group may be substituted by one or more substituent(s) selected from the group consisting of halogen atoms and a hydroxyl group,
R2 represents a C1-C10 alkyl group, an aryl group, a C1-C10 alkylester group, a C1-C10 alkylketone group or an arylketone group,
R3 and R4 independently represents a C1-C4 alkyl group, and
n represents an integer of 1 to 3.
Thus, the present invention provides a process for easily and economically preparing various alkyl aryl sulfide derivatives of Chemical Formula (III) by reacting a compound of Chemical Formula (I) with a compound of Chemical Formula (II) via Process (A) or (B) without any separation or purification stage.
Among the compounds represented by Chemical Formula (III) which is prepared via Process (A) or (B) in the Reaction Scheme, novel compounds are 2-(pent-2-ynylsulfanyl)-4-fluorophenol, 2-(5-phenylpentylsulfanyl)-4-fluorophenol, 2-(cyclohexylmethylsulfanyl)-4-fluorophenol, 4-((2-(1,3-dioxolan-2-yl)ethylsulfanyl)phenol, 2-(2-hydroxyhex-5-enylsulfanyl)-4-fluorophenol, 4-((tert-butoxycarbonyl)methylsulfanyl)benzoic acid, 3-(2-(1,3-dioxolan-2-yl)ethylsulfanyl)benzoic acid, 3-(2-hydroxyhex-5-enylsulfanyl)benzoic acid, 2-(4-(benzylsulfanyl)phenyl)ethanol, 2-(3-(benzylsulfanyl)phenyl)ethanol, 1-((4-(hydroxymethyl)phenyl)sulfanyl)hex-5-en-2-ol, (4-(2-(1,3-dioxolan-2-yl)ethylsulfanyl)phenyl)methanol, tert-butyl 2-((4-(hydroxymethyl)phenyl)sulfanyl)acetate, (4-(pent-2-ynylsulfanyl)phenyl)methanol, 4-(benzylthio)-2-bromobenzenamine, 4-(5-phenylpentylthio)benzenamine, 1-(4-aminopentylthio)hex-5-en-2-ol, 2-[4-(benzylthio)phenyl]ethanamine, tert-butyl 2-[4-(2-aminoethyl)phenylthio]-2-methylpropionate, benzyl 2-trifluoromethylphenyl sulfide, benzyl 2-methoxyphenylsulfide, 2-bromo-6-(2-[1,3]dioxolan-2-yl-ethylsulfanyl)pyridine, 5-[4-(tert-butyldimethylsilanyloxy)-3-methylphenylsulfanyl]-4-methyl-2-[(4-trifluoromethyl)phenyl]thiazol, 4-benzylsulfanyl-2-methyl-phenylamine, tert-butyl [4-(2-aminoethyl)phenylthio]acetate, 4-benzylsulfanyl-2,6-dimethylphenol, 4-benzylsulfanyl-2-chlorophenol, 4-benzylsulfanyl-4-fluorophenol, (4-benzylsulfanylphenyl)methanol, tert-butyl(4-hydroxyphenylsulfanyl)acetate, and 2-methyl-4-[[[4-methyl-2-[(4-trifluoromethyl)phenyl]thiazol-5-yl]methyl]sulfanyl]phenol.
Thus the present invention provides useful novel compounds of use.
Other and further objects, features and advantages of the invention will appear more fully from the following description.
In the Reaction Scheme shown above, A represents CH or a nitrogen atom contained in the aryl compound having a resonance structure.
X1 represents a halogen atom. As the halogen atom, mentioned can be a fluorine atom, chlorine atom, bromine atom, and iodine atom. Among them, a bromine atom or an iodine atom is preferable.
X2 means a leaving group. A conventional leaving group, specifically a halogen atom, a methansulfonyl oxy group, a p-toluenesulfonyloxy group may be employed. Herein, the halogen atoms include a fluorine atom, a chlorine atom, a bromine atom and an iodine atom. Among them, a halogen atom is preferable, a chlorine atom, a bromine atom, or an iodine atom being more preferable.
X3, a halogen atom of Grignard reagent, represents a chlorine atom, a bromine atom or an iodine atom.
R1 represents a hydrogen atom, a halogen atom, a C1-C7 alkyl group, a C1-C7 alkyloxy group, a C1-C7 alkylthiooxy group, an aryl group, a hydroxyl group, a hydroxymethyl group, a hydroxyethyl group, an amine group, an aminomethyl group, an aminoethyl group, an alkylamine group, a dialkylamine group or a carboxy group, where in the alkyl group may be substituted by one or more substituent(s) selected from the group consisting of halogen atoms and a hydroxyl group. Each substituent R1 may have ortho-, meta- or para-position with respect to the halogen atom (X1), and number of the substituent(s) is from 1 to 3.
R2 represents a C1-C10 alkyl group, an aryl group, a C1-C10 alkylester group, a C1-C10 alkylketone group or an arylketone group.
R3 and R4 independently represent a C1-C4 alkyl group, such as methyl, ethyl, propyl, isopropyl, n-butyl, sec-butyl and tert-butyl group.
In the preparation process according to the present invention, the compound of Chemical Formula (I) employed as raw material is well known in the art and commercially available.
The preparation process according to the invention is now described in detail.
An alkyl aryl sulfide compound represented by Chemical Formula (III) is obtained by reacting a compound represented by Chemical Formula (I) with an alkyl lithium organometallic reagent and sulfur, and then with a compound represented by Chemical Formula (II).
Dry solvent such as diethyl ether, tetrahydrofuran, hexane and heptane is used in this process either alone or in a mixture of the two or more. Among them, diethylether, tetrahydrofuran, and a mixture of diethyl ether and tetrahydrofuran are the most preferable.
The alkyl lithium organometallic reagents employed in the halogen-metal substitution include n-butyl lithium, sec-butyl lithium, tert-butyl lithium, and the like. The amount of alkyl lithium organometallic reagent employed is usually from 1 to 3 equivalents with respect to the compound of Chemical Formula (I), most preferably from 1 to 1.2 equivalents in case of n-butyl lithium or sec-butyl lithium, and from 2 to 2.2 equivalents in case of tert-butyl lithium.
Sulfur used in this process is in a powdery state colored pale yellow, and the amount is usually from 1 to 3 equivalents, preferably from 1 to 1.2 equivalents with respect to the compound of Chemical Formula (I).
The reaction temperature varies depending upon the solvent employed, but usually is from −100° C. to 25° C. Preferably the substitution of halogen with metal and introduction of sulfur are carried out at −75° C., and the reaction with compound of Chemical Formula (II) at room temperature (25° C.). The reaction time varies depending on the reaction temperature and the type of solvent employed, but usually is from 30 minutes to 6 hours, preferably 1 hour or less.
In preparing an alkyl aryl sulfide compound represented by Chemical Formula (III) where the substituent of the compound of Chemical Formula (I) is a hydrogen-donating substituent (—OH, —CH2OH, —CH2CH2OH, —NH2, —NRH, —CH2NH2, —CH2CH2NH2, —COOH), the hydrogen-donating substituent is firstly protected with Grignard reagent, and then reacted with an alkyl lithium organometallic reagent and sulfur, followed by a compound represented by Chemical Formula (II), to obtain a compound of Chemical Formula (III).
As dry solvent used in this process, diethyl ether, tetrahydrofuran, hexane or heptane may be used alone or in a combination of the two or more. Among them, most preferable are diethyl ether, tetrahydrofuran, or a mixture of diethyl ether and tetrahydrofuran.
As the Grignard reagent which protects the hydrogen-donating substituent (—OH, —CH2OH, —CH2CH2OH, —NH2, —NRH, —CH2NH2, —CH2CH2NH2, —COOH), employed may be CH3MgCl, CH3MgBr, CH3MgI, CH3CH2MgCl, CH3CH2MgBr, CH3CH2MgI, CH3CH2CH2MgCl, CH3CH2CH2MgBr, CH3CH2CH2MgI, (CH3)2CHMgCl, (CH3)2CHMgBr, (CH3)2CHMgI, CH3CH2CH2CH2MgCl, CH3CH2CH2CH2MgBr, CH3CH2CH2CH2MgI, C2H5CHCH3MgCl, C2H5CHCH3MgBr, C2H5CHCH3MgI, (CH3)3CMgCl, (CH3)3CMgBr, (CH3)3CMgI, or the like. Among them, R3MgCl and R3MgBr are preferable, (CH3)2CHMgC1 and CH3CH2CH2CH2MgCl being more preferable.
The alkyl lithium organometallic reagents which can be employed in halogen-metal substitution reaction include n-butyl lithium, sec-butyl lithium, tert-butyl lithium, and the like. The amount of alkyl lithium organometallic reagent employed is usually from 1 to 3 equivalents, more preferably from 1 to 1.2 equivalents in case of n-butyl lithium or sec-butyl lithium, from 2 to 2.2 equivalents in case of tert-butyl lithium.
Sulfur used in this process is in a powdery state colored pale yellow, and the amount is usually from 1 to 3 equivalents, preferably from 1 to 1.2 equivalents with respect to the compound of Chemical Formula (I).
The reaction temperature varies depending upon the solvent employed, but usually is from −100° C. to 25° C. Preferably, protection of the hydrogen-donating substituent is carried out at 0° C. to 25° C., the substitution of halogen with metal and introduction of sulfur at −75° C., and the reaction with compound of Chemical Formula (II) at room temperature (25° C.). The reaction time varies depending on the reaction temperature and the type of solvent employed, but usually is from 30 minutes to 6 hours, preferably 2 hours or less.
The present invention regarding alkyl aryl sulfide compounds of Chemical Formula (III) thus obtained and processes for preparing the same are very important in production process of primary intermediates in organochemical reactions and therapeutic agents containing alkyl aryl sulfide functional groups among therapeutic agents for treating various diseases.
The present invention is described specifically below by way of Examples. However, the present invention is not restricted to these Examples.
1-Bromo-2-(trifluoromethyl)-benzene 271 μl (2 mmol) was completely dissolved in dry tetrahydrofuran 15 ml under nitrogen atmosphere, and the mixture was cooled to −78° C. To the mixture, n-butyl lithium 1.25 ml (1.6M in hexane, 1.0 equivalent) was slowly added for 1 minute. After stirring additional 10 minutes, sulfur powder 64 mg (2 mmol, 1.0 equivalent) was added at once at the same temperature. After stirring the mixture at the same temperature for additional 10 minutes to completely dissolve sulfur, benzyl bromide 236 μl (2 mmol, 1.0 equivalent) was slowly added thereto. Reaction was carried out so that the temperature of overall reaction mixture was raised to room temperature in 20 minutes. The reaction was monitored by TLC, and when the reaction was completed, 15 ml of aqueous ammonium chloride solution was added thereto to quench the reaction. The organic phase was extracted by using ethyl acetate. Moisture contained in the organic phase was removed by using magnesium sulfate. After filtration, the solvent was evaporated under reduced pressure. The residue was purified by silica gel column chromatography to obtain the title compound 440 mg (yield: 82%).
1H-NMR (300 MHz, CDCl3) δ: 7.63 (d, 1H, J=7.6 Hz), 7.38 (d, 2H, J=3.4 Hz), 7.32˜7.23 (m, 6H), 4.15 (s, 2H).
13C-NMR (75.5 MHz, CDCl3) δ: 136.8, 136.2, 132.3, 132.2, 129.9, 129.4, 128.9, 127.2 (q, J=3.7 Hz), 123.3, 39.7.
The same procedure as described in Example 1 was repeated but 1-bromo-2-(trifluoromethyl)-benzene was replaced with 1-bromo-3-(trifluoromethyl)-benzene 276 μl (2 mmol). After purification, the title compound 381 mg (yield: 71%) was obtained.
1H-NMR (300 MHz, CDCl3) δ: 7.51 (br s, 1H), 7.39 (t, 2H), 7.33 (d, 1H), 7.28 (m, 5H), 4.13 (s, 2H).
13C-NMR (75.5 MHz, CDCl3) δ: 138.3, 137.0, 133.0, 131.6 (q, J=32 Hz), 129.5, 129.2, 129.0, 128.9, 127.9, 126.5 (q, J=3.7 Hz), 123.3, 39.1.
The same procedure as described in Example 1 was repeated but 1-bromo-2-(trifluoromethyl)-benzene was replaced with 1-bromo-4-(trifluoromethyl)-benzene 276 μl (2 mmol). After purification, the title compound 515 mg (yield: 96%) was obtained.
1H-NMR (300 MHz, CDCl3) δ: 7.48 (d, 2H, J=8.2 Hz), 7.36˜7.25 (m, 7H), 4.19 (s, 2H).
13C-NMR (75.5 MHz, CDCl3) δ: 142.5, 136.7, 129.1, 129.0, 128.3, 127.9, 126.0 (q, J=3.9 Hz), 38.1.
The same procedure as described in Example 1 was repeated but 1-bromo-2-(trifluoromethyl)-benzene was replaced with 2-bromoanizol 248 μl (2 mmol). After purification, the title compound 350 mg (yield: 76%) was obtained.
1H-NMR (300 MHz, CDCl3) δ: 7.30˜7.18 (m, 7H), 6.84 (m, 2H, J=7.8 Hz), 4.09 (s, 2H), 3.88 (s, 3H).
13C-NMR (75.5 MHz, CDCl3) δ: 157.9, 137.9, 130.8, 129.3, 128.8, 128.0, 127.4, 124.8, 121.4, 110.9, 56.2, 37.7.
The same procedure as described in Example 1 was repeated but 1-bromo-2-(trifluoromethyl)-benzene was replaced with 3-bromoanizol 251 μl (2 mmol). After purification, the title compound 332 mg (yield: 72%) was obtained.
1H-NMR (300 MHz, CDCl3) δ: 7.32˜7.24 (m, 5H), 7.16 (t, 1H), 6.86 (d, 1H), 6.82 (t, 1H), 6.65 (dd, 1H), 4.11 (s, 2H), 3.73 (s, 3H).
13C-NMR (75.5 MHz, CDCl3) δ: 160.1, 138.1, 137.8, 130.0, 129.2, 128.9, 127.6, 122.1, 115.2, 112.6, 55.6, 39.2.
The same procedure as described in Example 1 was repeated but 1-bromo-2-(trifluoromethyl)-benzene was replaced with 4-bromoanizol 250 μl (2 mmol). After purification, the title compound 424 mg (yield: 92%) was obtained.
1H-NMR (300 MHz, CDCl3) δ: 7.28˜7.16 (m, 7H), 6.77 (d, 2H, J=8.6 Hz), 3.97 (s, 2H), 3.76 (s, 3H).
13C-NMR (75.5 MHz, CDCl3) δ: 159.6, 138.5, 134.5, 129.8, 129.3, 128.8, 127.3, 114.8, 55.7, 41.6.
The same procedure as described in Example 1 was repeated but 1-bromo-2-(trifluoromethyl)-benzene was replaced with 4-bromobiphenyl 468 μl (2 mmol). After purification, the title compound 514 mg (yield: 93%) was obtained.
1H-NMR (300 MHz, CDCl3) δ: 7.70˜7.20 (m, 14H), 4.15 (s, 2H).
13C-NMR (75.5 MHz, CDCl3) δ: 140.8, 139.6, 137.8, 135.9, 131.8, 130.4, 129.3, 129.2, 128.9, 128.3, 127.9, 127.7, 127.6, 127.4, 127.3, 39.5.
4-bromoanizol 374 mg (2 mmol) was completely dissolved in dry tetrahydrofuran 15 ml under nitrogen atmosphere, and the mixture was cooled to −78° C. To the mixture, n-butyl lithium 1.25 ml (1.6M in hexane, 1.0 equivalent) was slowly added for 1 minute. After stirring additional 10 minutes, sulfur powder 64 mg (2 mmol, 1.0 equivalent) was added at once at the same temperature. After stirring the mixture at the same temperature for additional 5 minutes to completely dissolve sulfur, tert-butyl bromoacetate 295 μl (2 mmol, 1.0 equivalent) was slowly added. Reaction was carried out so that the temperature of overall reaction mixture was raised to room temperature in 20 minutes. When the reaction was completed, aqueous ammonium chloride solution was added thereto to quench the reaction. The organic phase was extracted by using ethyl acetate and aqueous sodium chloride solution. Moisture contained in the organic phase was removed by using magnesium sulfate. After filtration, the solvent was evaporated under reduced pressure. The residue was purified by silica gel column chromatography to obtain the title compound 488 mg (yield: 96%).
1H-NMR (300 MHz, CDCl3) δ: 7.42 (d, 2H, J=8.8 Hz), 6.83 (d, 2H, J=8.8 Hz), 3.79 (s, 3H), 3.43 (s, 2H), 1.39 (s, 9H).
13C-NMR (75.5 MHz, CDCl3) δ: 169.4, 159.9, 134.3, 125.7, 114.9, 81.9, 55.7, 40.0, 28.3.
The same procedure as described in Example 8 was repeated but tert-butyl bromoacetate was replaced with allylbromide 173 μl (2 mmol). After purification, the title compound 328 mg (yield: 91%) was obtained.
1H-NMR (300 MHz, CDCl3) δ: 7.33 (d, 2H, J=9.8 Hz), 6.82 (d, 2H, J=9.8 Hz), 5.82 (m, 1H), 5.01 (s, 1H), 4.97 (dd, 1H, J=8.0 and 1.3 Hz), 3.78 (s, 3H), 3.42 (d, 2H, J=7 Hz).
13C-NMR (75.5 MHz, CDCl3) δ: 159.5, 134.4, 134.3, 126.2, 117.6, 114.8, 55.7, 39.7, 30.7.
The same procedure as described in Example 8 was repeated but using reaction intermediate, 1-bromobutane, instead of using additional butylhalide. After purification, the title compound 295 mg (yield: 75%) was obtained.
1H-NMR (300 MHz, CDCl3) δ: 7.32 (d, 2H, J=8.8 Hz), 6.83 (d, 2H, J=8.7 Hz), 3.79 (s, 3H), 2.82 (t, 2H), 1.55 (m, 2H), 1.40 (m, 2H), 0.89 (t, 3H).
13C-NMR (75.5 MHz, CDCl3) δ: 159.1, 133.3, 127.3, 114.9, 55.7, 35.9, 31.8, 22.2, 14.0.
The same procedure as described in Example 8 was repeated but tert-butyl bromoacetate was replaced with chloroacetone 159 μl (2 mmol). After purification, the title compound 357 mg (yield: 91%) was obtained.
1H-NMR (300 MHz, CDCl3) δ: 7.35 (d, 2H, J=8.8 Hz), 6.83 (d, 2H, J=8.8 Hz), 3.79 (s, 3H), 3.54 (s, 2H), 2.26 (s, 3H).
13C-NMR (75.5 MHz, CDCl3) δ: 204.0, 160.0, 134.0, 125.0, 115.2, 55.7, 46.9, 28.4.
The same procedure as described in Example 8 was repeated but tert-butyl bromoacetate was replaced with 2-bromoacetophenone 398 mg (2 mmol). After purification, the title compound 486 mg (yield: 94%) was obtained.
1H-NMR (300 MHz, CDCl3) δ: 7.90 (d, 2H, J=7.2 Hz), 7.55 (t, 1H), 7.43 (t, 2H), 7.34 (d, 2H, J=8.8 Hz), 6.80 (d, 2H, J=6.8 Hz), 4.12 (s, 2H), 3.76 (s, 3H).
13C-NMR (75.5 MHz, CDCl3) δ: 194.7, 160.1, 135.9, 135.0, 133.7, 129.1, 129.0, 125.0, 115.1, 55.7, 43.2.
2,6-Dibromo pyridine 476 mg (2 mmol) was completely dissolved in dry tetrahydrofuran 15 ml under nitrogen atmosphere, and the mixture was cooled to −78° C. To the mixture, butyl lithium 1.25 ml (1.6M in hexane, 1.0 equivalent) was slowly added for 1 minute. After stirring additional 10 minutes, sulfur powder 64 mg (2 mmol, 1.0 equivalent) was added at once at the same temperature. After stirring the mixture at the same temperature for additional 5 minutes to completely dissolve sulfur powder, 2-(2bromoethyl)-1,3-dioxolan 261 μl (2 mmol, 1.0 equivalent) was slowly added. Reaction was carried out so that the temperature of overall reaction mixture was raised to room temperature in 20 minutes. when the reaction was completed, aqueous ammonium chloride solution was added thereto to quench the reaction. The organic phase was extracted by using ethyl acetate and aqueous sodium chloride solution. Moisture contained in the organic phase was removed by using magnesium sulfate. After filtration, the solvent was evaporated under reduced pressure. The residue was purified by silica gel column chromatography to obtain the title compound 459 mg (yield: 79%).
1H-NMR (300 MHz, CDCl3) δ: 7.35˜7.11 (m, 3H), 5.05 (t, 1H), 4.02 (m, 2H), 3.91 (m, 2H), 3.27 (t, 2H), 2.11 (m, 2H)
13C-NMR (75.5 MHz, CDCl3) δ: 160.7, 142.0, 138.3, 123.5, 121.0, 103.6, 65.3, 33.7, 25.3.
4-bromobenzoic acid 402 mg (2 mmol) was completely dissolved in dry tetrahydrofuran 15 ml under nitrogen atmosphere, and the mixture was cooled to −78° C. To the mixture, butyl lithium 2.5 ml (1.6M in hexane, 1.0 equivalent) was slowly added for 1 minute. After stirring additional 10 minutes, sulfur powder 64 mg (2 mmol, 1.0 equivalent) was added at once at the same temperature. After stirring the mixture at the same temperature for additional 5 minutes to completely dissolve sulfur powder, 4-bromobenzylbromide 250 mg (2 mmol, 1.0 equivalent) was slowly added. Reaction was carried out so that the temperature of overall reaction mixture was raised to room temperature in 20 minutes. when the reaction was completed, aqueous ammonium chloride solution was added thereto to quench the reaction. The organic phase was extracted by using ethyl acetate and aqueous sodium chloride solution. Moisture contained in the organic phase was removed by using magnesium sulfate. After filtration, the solvent was evaporated under reduced pressure. The residue was purified by silica gel column chromatography to obtain the title compound 575 mg (yield: 89%).
1H-NMR (300 MHz, DMSO-d6) δ: 12.9 (br s, 1H), 7.82 (d, 2H, J=8.4 Hz), 7.50 (d, 2H, J=8.4 Hz), 7.40 (d, 2H, J=11.8 Hz), 7.37 (d, 2H, J=11.8 Hz), 4.33 (s, 2H).
13C-NMR (75.5 MHz, DMSO-d6) δ: 167.7, 143.3, 137.4, 132.2, 131.8, 130.5, 128.4, 127.5, 121.1, 35.4.
2-bromobenzoic acid 402 mg (2 mmol) was completely dissolved in dry tetrahydrofuran 15 ml under nitrogen atmosphere, and the mixture was cooled to 0° C. To the mixture, isopropylmagnesium chloride 1.0 ml (2.0 mmol, 2.0 M-ether, 1.0 equivalent) was slowly added at the same temperature. After 10 minutes, the mixture was cooled to −78° C. tert-Butyl lithium 2.35 μl (4.0 mmol, 1.7 M-pentane, 2.0 equivalent) was slowly added for 1 minute. Sulfur powder 64 mg (2 mmol) dissolved in dry tetrahydrofuran 3.0 μl was added. Reaction was carried out so that the temperature of overall reaction mixture was raised to room temperature in 30 minutes. Again, the mixture was cooled to 0° C. Benzylbromide 238 μl (2 mmol, 1.0 equivalent) was slowly added to the mixture. After 20 minutes at room temperature, aqueous ammonium chloride solution was added thereto to quench the reaction. The organic phase was extracted by using ethyl acetate and 5% aqueous hydrochloric acid solution. Moisture contained in the organic phase was removed by using magnesium sulfate. After filtration, the solvent was evaporated under reduced pressure. The residue was purified by silica gel column chromatography to obtain the title compound 429 mg (yield: 88%).
1H-NMR (300 MHz, DMSO-d6) δ: 13.00 (s, 1H) 7.89-7.86 (m, 1H), 7.49-7.20 (m, 8H), 4.19 (s, 2H).
13C-NMR (75 MHz, DMSO-d6) δ: 168.27, 142.07, 137.49, 133.18, 131.77, 130.02, 129.33, 128.58, 128.01, 126.59, 124.85, 36.57
The same procedure as described in Example 15 was repeated but 2-bromobenzoic acid was replaced with 3-bromobenzoic acid 402 mg (2 mmol). After purification, the title compound 473 mg (yield: 97%) was obtained.
1H-NMR (300 MHz, DMSO-d6) δ: 13.04 (s, 1H), 8.12-7.21 (m, 9H), 4.28 (s, 2H).
13C-NMR (75 MHz, DMSO-d6) δ: 167.63, 137.96, 137.79, 133.22, 132.34, 130.11, 130.06, 129.69, 129.48, 129.41, 129.26, 128.01, 127.54, 37.36.
The same procedure as described in Example 15 was repeated but 2-bromobenzoic acid was replaced with 4-bromobenzoic acid 402 mg (2 mmol). After purification, the title compound 449 mg (yield: 92%) was obtained.
1H-NMR (300 MHz, DMSO-d6) δ: 12.85 (s, 1H), 7.82-7.79 (m, 2H), 7.41-7.20 (m, 7H), 4.33 (s, 2H).
13C-NMR (75 MHz, DMSO-d6) δ: 167.77, 143.90, 137.64, 130.56, 129.71, 129.33, 128.29, 128.09, 127.30, 36.2.
The same procedure as described in Example 15 was repeated but 2-bromobenzoic acid and benzylbromide were replaced with 4-bromobenzoic acid 402 mg (2 mmol) and tert-butyl bromoacetate 295 μl (2 mmol, 1.0 equivalent), respectively. After purification, the title compound 472 mg (yield: 88%) was obtained.
1H-NMR (300 MHz, DMSO-d) δ: 12.40 (br, 1H), 8.02-7.95 (m, 2H), 7.40-7.37 (m, 2H), 3.60 (s, 2H), 1.43 (s, 9H)
13C-NMR (75 MHz, DMSO-d) δ: 172.28, 168.54, 144.25, 130.95, 127.21, 126.89, 82.97, 36.30, 28.
The same procedure as described in Example 15 was repeated but 2-bromobenzoic acid and benzylbromide were replaced with 3-bromobenzoic acid 402 mg (2 mmol) and 2-(2-bromomethyl)-1,3-dioxolan 235 μl (2 mmol, 1.0 equivalent), respectively. After purification, the title compound 416 mg (yield: 82%) was obtained.
1H-NMR (300 MHz, DMSO-d6) δ: 11.95 (br, 1H), 8.07-8.06 (m, 1H), 7.92-7.89 (m, 1H), 7.57-7.54 (m, 1H), 7.41-7.35 (m, 1H), 5.03-5.00 (m, 1H), 4.02-3.85 (m, 4H) 3.11-3.06 (m, 2H), 2.07-2.00 (m, 2H).
13C-NMR (75 MHz, DMSO-d6) δ: 172.01, 137.99, 134.14, 130.60, 130.51, 129.37, 127.90, 103.32, 65.41, 33.70, 27.
The same procedure as described in Example 15 was repeated but 2-bromobenzoic acid and benzylbromide were replaced with 3-bromobenzoic acid 402 mg (2 mmol) and 1.2-epoxy-5-hexene 228 μl (2 mmol, 1.0 equivalent), respectively. After purification, the title compound 418 mg (yield: 83%) was obtained.
1H-NMR (300 MHz, DMSO-d6) δ: 8.09-8.10 (m, 1H), 7.92-7.94 (m, 1H), 7.58-7.62 (m, 1H), 7.37-7.42 (m, 1H), 5.76-5.82 (m, 1H). 4.95-5.07 (m, 2H), 3.75 (m, 1H), 3.18-3.24 (m, 1H), 2.91-2.99 (m, 1H), 2.17-2.24 (m, 2H), 1.63-1.70 (m, 1H).
13C-NMR (75 MHz, DMSO-d6) δ: 171.12, 138.27, 137.10, 135.00, 131.16, 130.62, 129.54, 128.50, 115.59, 69.50, 42.09, 35.58, 30.29.
1,4-Dibromo benzene 256 μl (2 mmol) was completely dissolved in dry tetrahydrofuran 15 ml under nitrogen atmosphere, and the mixture was cooled to −78° C. To the mixture, butyl lithium 1.25 ml (1.6M in hexane, 1.0 equivalent) was slowly added for 1 minute. After stirring additional 10 minutes, sulfur powder 64 mg (2 mmol, 1.0 equivalent) was added at once at the same temperature. After stirring the mixture at the same temperature for additional 5 minutes to completely dissolve sulfur, benzyl bromide 236 μl (2 mmol, 1.0 equivalent) was slowly added. Reaction was carried out so that the temperature of overall reaction mixture was raised to room temperature in 20 minutes. When the reaction was completed, aqueous ammonium chloride solution was added thereto to quench the reaction. The organic phase was extracted by using ethyl acetate and aqueous sodium chloride solution. Moisture contained in the organic phase was removed by using magnesium sulfate. After filtration, the solvent was evaporated under reduced pressure. The residue was purified by silica gel column chromatography to obtain the title compound 491 mg (yield: 88%).
1H-NMR (300 MHz, CDCl3) δ: 7.36 (d, 2H, J=8.6 Hz), 7.28 (m, 5H), 7.14 (d, 2H, J=8.6 Hz), 4.08 (s, 2H).
13C-NMR (75.5 MHz, CDCl3) δ: 137.4, 135.8, 132.2, 131.9, 128.9, 127.7, 120.7, 39.5.
mesityl bromide 300 μl (2 mmol) was completely dissolved in dry tetrahydrofuran 15 ml under nitrogen atmosphere, and the mixture was cooled to −78° C. To the mixture, butyl lithium 1.25 ml (1.6M in hexane, 1.0 equivalent) was slowly added for 1 minute. After stirring additional 10 minutes, sulfur powder 64 mg (2 mmol, 1.0 equivalent) was added at once at the same temperature. After stirring the mixture at the same temperature for additional 5 minutes to completely dissolve sulfur, phenacyl bromide 398 mg (2 mmol, 1.0 equivalent) was slowly added. Reaction was carried out so that the temperature of overall reaction mixture was raised to room temperature in 20 minutes. when the reaction was completed, aqueous ammonium chloride solution was added thereto to quench the reaction. The organic phase was extracted by using ethyl acetate and aqueous sodium chloride solution. Moisture contained in the organic phase was removed by using magnesium sulfate. After filtration, the solvent was evaporated under reduced pressure. The residue was purified by silica gel column chromatography to obtain the title compound 498 mg (yield: 92%).
1H-NMR (300 MHz, CDCl3) δ: 7.87 (d, 2H, J=6.3 Hz), 7.55 (t, 1H, J=7.4 Hz), 7.42 (t. 2H, J=6.6 Hz), 6.89 (s, 2H) 3.92 (s, 2H), 2.38 (s, 6H), 2.25 (s, 3H).
13C-NMR (75.5 MHz, CDCl3) δ: 194.9, 143.5, 142.2, 139.2, 135.9, 133.6, 129.5, 129.1, 128.9, 41.2, 22.1, 21.4.
2-iodoaniline 438 mg (2 mmol) was completely dissolved in dry tetrahydrofuran 15 ml under nitrogen atmosphere. To the mixture, isopropylmagnesium chloride 2.0 ml (2.0 M-ether, 2.0 equivalent) was slowly added at 0° C. After 10 minutes at room temperature, the mixture was cooled to −78° C. tert-Butyl lithium 1.18 ml (1.7 M-pentane, 2.0 equivalent) was slowly added for 1 minute. After stirring additional 10 minutes, sulfur powder 64 mg (2 mmol, 1.0 equivalent) was added at once at the same temperature. Reaction was carried out so that the temperature of overall reaction mixture was raised to room temperature in 25 minutes. Again, the mixture was cooled to 0° C. Benzylbromide 236 μl (2 mmol, 1.0 equivalent) was slowly added to the mixture. After 20 minutes at room temperature, when the reaction was completed, aqueous ammonium chloride solution was added thereto to quench the reaction. The organic phase was extracted by using ethyl acetate and aqueous sodium chloride solution. After filtration, the solvent was evaporated under reduced pressure. The residue was purified by silica gel column chromatography to obtain the title compound 254 mg (yield: 59%).
1H-NMR (300 MHz, CDCl3) δ: 7.23˜7.12 (m, 7H), 6.68 (d, 1H, J=9.2 Hz), 6.58 (t, 1H, J=17.4 and 8.8 Hz), 4.23 (br s, 2H), 3.89 (s, 2H).
13C-NMR (75.5 MHz, CDCl3) δ: 148.8, 138.5, 136.7, 130.2, 129.1, 128.6, 127.2, 118.7, 115.1, 39.8.
The same procedure as described in Example 23 was repeated but 2-iodoaniline was replaced with 3-iodoaniline 241 μl (2 mmol). After purification, the title compound 284 mg (yield: 66%) was obtained.
1H-NMR (300 MHz, CDCl3) δ: 7.29 (m, 5H), 7.03 (t, 1H, J=15.7 and 7.9 Hz), 7.55 (d, 1H, J=8.5 Hz), 6.61 (t, 1H, J=2 Hz), 6.45 (dd, 1H, J=8.8 and 1.8 Hz), 4.09 (s, 2H), 3.60 (br s, 2H).
13C-NMR (75.5 MHz, CDCl3) δ: 146.9, 137.7, 137.6, 129.8, 129.0, 128.7, 127.3, 119.7, 115.9, 113.4, 38.9.
The same procedure as described in Example 23 was repeated but 2-iodoaniline was replaced with 3-bromoaniline 218 μl (2 mmol). After purification, the title compound 198 mg (yield: 46%) was obtained.
1H-NMR (300 MHz, CDCl3) δ: 7.29 (m, 5H), 7.03 (t, 1H, J=15.7 and 7.9 Hz), 7.55 (d, 1H, J=8.5 Hz), 6.61 (t, 1H, J=2 Hz), 6.45 (dd, 1H, J=8.8 and 1.8 Hz), 4.09 (s, 2H) 3.60 (br s, 2H).
13C-NMR (75.5 MHz, CDCl3) δ: 146.9, 137.7, 137.6, 129.8, 129.0, 128.7, 127.3, 119.7, 115.9, 113.4, 38.9.
The same procedure as described in Example 23 was repeated but 2-iodoaniline was replaced with 4-iodoaniline 438 mg (2 mmol). After purification, the title compound 396 mg (yield: 92%) was obtained.
1H-NMR (300 MHz, CDCl3) δ: 7.21 (m, 5H), 7.11 (d, 2H, J=8.6 Hz), 6.54 (d, 2H, J=8.6 Hz), 3.92 (s, 2H), 3.66 (br s, 2H).
13C-NMR (75.5 MHz, CDCl3) δ: 146.4, 138.6, 134.9, 129.1, 128.5, 127.0, 123.1, 115.6, 41.9.
The same procedure as described in Example 23 was repeated but 2-iodoaniline was replaced with 4-iodo-2-methylaniline 466 mg (2 mmol). After purification, the title compound 381 mg (yield: 83%) was obtained.
1H-NMR (300 MHz, CDCl3) δ: 7.23 (m, 5H), 7.03 (s, 1H), 7.01 (d, 1H, J=8.1 Hz), 6.53 (d, 1H, J=8.1 Hz), 3.93 (s, 2H), 3.61 (br s, 2H), 2.07 (s, 3H).
13C-NMR (75.5 MHz, CDCl3) δ: 144.6, 138.7, 135.7, 132.3, 129.1, 128.4, 127.0, 123.1, 122.9, 115.4, 41.9, 17.3.
The same procedure as described in Example 23 was repeated but 2-iodoaniline was replaced with 2,4-dibromobenzenamine 502 mg (2 mmol). After purification, the title compound 435 mg (yield: 74%) was obtained.
1H-NMR (300 MHz, CDCl3) δ 7.39 (d, 1H), 7.29˜7.12 (m, 5H), 7.04 (dd, 1H), 6.61 (d, 1H), 4.11 (bs, 2H), 3.93 (s, 2H).
13C-NMR (75.5 MHz, CDCl3) δ 144.2, 138.4, 137.6, 134.0, 129.4, 128.8, 127.5, 124.5, 116.0, 109.3, 42.1.
The same procedure as described in Example 23 was repeated but 2-iodoaniline and benzylbromide were replaced with 4-iodobenzenamine 438 mg (2 mmol) and 4-(bromomethyl)benzonitrile 392 mg (2 mmol), respectively. After purification, the title compound 428 mg (yield: 89%) was obtained.
1H-NMR (300 MHz, CDCl3) δ 7.50 (dt, 2H), 7.19 (d, 2H), 7.05 (dt, 2H), 6.54 (dt, 2H), 3.89 (s, 2H), 3.75 (bs, 2H).
13C-NMR (75.5 MHz, CDCl3) δ 147.0, 144.5, 135.6, 132.2, 129.8, 121.3, 119.1, 115.6, 110.7, 41.8.
The same procedure as described in Example 23 was repeated but 2-iodoaniline and benzylbromide were replaced with 4-iodobenzenamine 438 mg (2 mmol) and 3-bromo-2-methylprop-1-ene 270 mg (2 mmol), respectively. After purification, the title compound 333 mg (yield: 93%) was obtained.
1H-NMR (300 MHz, CDCl3) δ 7.21 (dt, 2H), 6.59 (dt, 2H), 4.67 (m, 2H), 3.65 (bs, 2H), 3.35 (s, 2H), 1.83 (s, 3H).
13C-NMR (75.5 MHz, CDCl3) δ 146.2, 141.6, 134.7, 123.5, 115.6, 113.8, 44.8, 21.1. HRMS (EI) Calcd for C10H13NS (M+) 179.0769, found 179.0768.
The same procedure as described in Example 23 was repeated but 2-iodoaniline and benzylbromide were replaced with 4-iodobenzenamine 438 mg (2 mmol) and 2-bromo-1-phenylethanone 498 mg (2 mmol), respectively. After purification, the title compound 448 mg (yield: 92%) was obtained.
1H-NMR (300 MHz, DMSO-d6) δ 7.91 (m, 2H), 7.56 (m, 1H), 7.44 (m, 2H), 7.22 (dt, 2H), 6.57 (dt, 2H), 4.07 (s, 2H), 3.76 (bs, 2H)
13C-NMR (75.5 MHz, DMSO-d6) δ 194.7, 147.1, 135.8, 135.5, 133.4, 129.0, 128.8, 121.5, 115.8, 43.5.
The same procedure as described in Example 23 was repeated but 2-iodoaniline and benzylbromide were replaced with 4-iodobenzenamine 438 mg (2 mmol) and t-butyl 2-bromoacetate 390 mg (2 mmol), respectively. After purification, the title compound 454 mg (yield: 95%) was obtained.
1H-NMR (300 MHz, DMSO-d6) δ 7.29 (dt, 2H), 6.60 (dt, 2H), 3.74 (bs, 2H), 3.37 (s, 2H), 1.40 (s, 9H).
13C-NMR (75.5 MHz, DMSO-d6) δ 169.7, 147.0, 135.0, 122.5, 115.8, 81.8, 40.6, 28.3.
The same procedure as described in Example 23 was repeated but 2-iodoaniline and benzylbromide were replaced with 4-iodobenzenamine 438 mg (2 mmol) and 1-(5-bromopentyl)benzen 454 mg (2 mmol), respectively. After purification, the title compound 456 mg (yield: 84%) was obtained.
1H-NMR (300 MHz, CDCl3) δ 7.29˜7.11 (m, 7H), 6.60 (dt, 2H), 3.50 (bs, 2H), 2.75 (t, 2H), 2.58 (t, 2H), 1.62˜1.53 (m, 4H), 1.47˜1.39 (m, 2H).
13C-NMR (75.5 MHz, CDCl3) δ 145.9, 142.8, 134.0, 129.5, 128.6, 128.4, 125.8, 115.8, 36.5, 36.0, 31.2, 29.5, 28.5.
The same procedure as described in Example 23 was repeated but 2-iodoaniline and benzylbromide were replaced with 4-iodobenzenamine 438 mg (2 mmol) and (bromomethyl)cyclohexane 354 mg (2 mmol), respectively. After purification, the title compound 359 mg (yield: 81%) was obtained.
1H-NMR (300 MHz, CDCl3) δ 7.42 (d, 2H, J=8.8 Hz), 7.21 (dt, 2H), 6.60 (dt, 2H), 3.66 (bs, 2H), 2.67 (d, 2H), 1.86 (d, 2H), 1.76˜1.57 (m, 3H), 1.54˜1.36 (m, 1H) 1.30˜1.08 (m, 3H), 1.02˜0.85 (m, 2H).
13C-NMR (75.5 MHz, CDCl3) δ 145.7, 139.0, 133.5, 115.8, 115.1, 44.1, 37.7, 32.9, 26.6, 26.3.
The same procedure as described in Example 23 was repeated but 2-iodoaniline and benzylbromide were replaced with 4-iodobenzenamine 438 mg (2 mmol) and 2-(but-3-enyl)oxiran 196 mg (2 mmol), respectively. After purification, the title compound 389 mg (yield: 87%) was obtained.
1H-NMR (300 MHz, CDCl3) δ 7.26 (dt, 2H), 6.61 (dt, 2H), 5.79 (m, 1H), 4.98 (m, 2H), 3.73 (bs, 2H), 3.59 (m, 1H), 2.97 (dd, 1H), 2.68 (dd, 1H), 2.59 (bs, 1H), 2.24 ˜2.05 (m, 2H), 1.66˜1.50 (m, 3H)
13C-NMR (75.5 MHz, CDCl3) δ 146.6, 138.4, 134.6, 122.1, 115.9, 115.0, 68.7, 44.9, 35.2, 30.2.
4-bromobenzylamine 445 mg (2 mmol) was completely dissolved in dry tetrahydrofuran 20 ml under nitrogen atmosphere. To the mixture, isopropylmagnesium chloride 3.0 ml (2.0 M-ether, 3.0 equivalent) was slowly added at 0° C. After 10 minutes at room temperature, the mixture was cooled to −78° C. tert-Butyl lithium 1.18 ml (1.7 M-pentane, 2.0 equivalent) was slowly added for 1 minute. After stirring additional 10 minutes, sulfur powder 64 mg (2 mmol, 1.0 equivalent) was added at once at the same temperature. Reaction was carried out so that the temperature of overall reaction mixture was raised to room temperature in 25 minutes. Again, the mixture was cooled to 0° C. Benzylbromide 236 μl (2 mmol, 1.0 equivalent) was slowly added to the mixture. After 20 minutes at room temperature, when the reaction was completed, aqueous ammonium chloride solution was added thereto to quench the reaction. The organic phase was extracted by using ethyl acetate and aqueous sodium chloride solution. After filtration, the solvent was evaporated under reduced pressure. The residue was purified by silica gel column chromatography to obtain the title compound 440 mg (yield: 96%).
1H-NMR (300 MHz, CDCl3) δ 7.28˜7.18 (m, 9H), 4.09 (s, 2H), 3.82 (s, 2H).
The same procedure as described in Example 36 was repeated but 4-bromobenzylamine was replaced with 2-(4-bromophenyl)ethanamine 400 mg (2 mmol). After purification, the title compound 477 mg (yield: 98%) was obtained.
1H-NMR (300 MHz, CDCl3) δ 7.28˜7.21 (m, 7H), 7.09 (d, 2H), 4.09 (s, 2H), 2.94 (t, 2H), 2.70 (t, 2H), 1.75 (bs, 2H)
13C-NMR (75.5 MHz, CDCl3) δ 138.4, 137.8, 134.0, 130.7, 129.6, 129.0, 128.7, 127.3, 43.5, 39.7, 29.9.
4-bromophenethylamine 400 mg (2 mmol) was completely dissolved in dry tetrahydrofuran 20 ml under nitrogen atmosphere, and the mixture was cooled to 0° C. To the mixture, isopropylmagnesium chloride 2.0 ml (4.0 mmol, 2.0 M-ether, 2.0 equivalent) was slowly added at the same temperature. After 15 minutes, the mixture was cooled to −78° C. tert-Butyl lithium 2.35 ml (4.0 mmol, 1.7 M-pentane, 2.0 equivalent) was slowly added for 1 minute. After 30 minute at the same temperature, sulfur powder 64 mg (2 mmol) dissolved in dry tetrahydrofuran 3.0 ml was added. Reaction was carried out so that the temperature of overall reaction mixture was raised to room temperature in 60 minutes. Again, the mixture was cooled to 0° C. tert-Butylbromoacetate 296 μl (2 mmol, 1.0 equivalent) was slowly added to the mixture. After 20 minutes at room temperature, the solvent was removed under reduced pressure. The organic phase was extracted by aqueous ammonium chloride solution (20 μl) and ethylacetate (3×20 μl). Moisture contained in the organic phase was removed by using magnesium sulfate. After filtration, the solvent was evaporated under reduced pressure. The residue was purified by silica gel column chromatography that using dichloromethane included 3% ammonia water and 10% methanol to obtain the title compound 504 mg (yield 94%).
1H-NMR (300 MHz, CDCl3) δ: 7.36 (d, 2H, J=8.1 Hz), 7.13 (d, 2H, J=8.1 Hz), 3.53 (s, 2H), 2.95 (t, 2H, J=6.9 Hz), 2.71 (t, 2H, J=6.9 Hz), 1.40 (s, 9H), 1.31 (br s, 2H).
13C-NMR (75.5 MHz, CDCl3) δ: 169.3, 139.2, 130.9, 129.8, 120.4, 82.2, 43.9, 40.1, 38.5, 28.3.
4-bromophenethylamine 397 mg (2 mmol) was completely dissolved in dry tetrahydrofuran 20 ml under nitrogen atmosphere, and the mixture was cooled to 0° C. To the mixture, isopropylmagnesium bromide 2.0 ml (4.0 mmol, 2.0 M-ether, 2.0 equivalent) was slowly added at the same temperature. After 15 minutes, the mixture was cooled to −78° C. tert-Butyl lithium 2.35 μl (4.0 mmol, 1.7 M-pentane, 2.0 equivalent) was slowly added for 1 minute. After 30 minute at the same temperature, sulfur powder 64 mg (2 mmol) dissolved in dry tetrahydrofuran 3.0 ml was added. Reaction was carried out so that the temperature of overall reaction mixture was raised to room temperature. After 60 minutes, the solvent was removed under reduced pressure. After calcium hydroxide 108 mg (2.0 mmol) was added, t-butyl-2-bromoisobutylate 373 μl (2.0 mmol) was added. The reaction mixture was heated with reflux for 1 hour at 80° C., and then cooled to room temperature. After the solvent was removed under reduced pressure, the organic phase was extracted by aqueous ammonium chloride solution (20 μl) and ethylacetate (3×20 μl). Moisture contained in the organic phase was removed by using magnesium sulfate. After filtration, the solvent was evaporated under reduced pressure. The residue was purified by silica gel column chromatography that using dichloromethane included 3% ammonia water and 10% methanol to obtain the title compound 545 mg (yield 92%).
1H-NMR (300 MHz, CDCl3) δ: 7.45 (d, 2H, J=88.0 Hz), 7.16 (d, 2H, J=8.0 Hz), 2.97 (t, 2H, J=7.0 Hz), 2.76 (t, 2H, J=7.0 Hz), 1.44 (s, 6H), 1.43 (s, 9H), 1.32 (br s, 2H).
13C-NMR (75.5 MHz, CDCl3) δ: 173.5, 141.5, 137.4, 129.8, 129.4, 129.2, 128.9, 81.3, 51.7, 43.8, 40.2, 28.3, 26.5.
Calculated value 295.1606,
Measured value 295.1605.
2-bromophenol 232 μl (2 mmol) was completely dissolved in dry tetrahydrofuran 15 ml under nitrogen atmosphere, and the mixture was cooled to 0° C. To the mixture, isopropylmagnesium chloride 1.0 ml (2.0 mmol, 2.0 M-ether, 2.0 equivalent) was slowly added at the same temperature. After 10 minutes, the mixture was cooled to −78° C. tert-Butyl lithium 2.35 μl (4.0 mmol, 1.7 M-pentane, 2.0 equivalent) was slowly added for 1 minute. After 30 minutes at the same temperature, sulfur powder 64 mg (2 mmol) dissolved in dry tetrahydrofuran 3.0 ml was added. Reaction was carried out so that the temperature of overall reaction mixture was raised to room temperature in 30 minutes. Again, the mixture was cooled to 0° C. Benzylbromide 236 μl (2 mmol, 1.0 equivalent) was slowly added to the mixture. After 20 minutes at room temperature, aqueous ammonium chloride solution was added thereto to quench the reaction. The organic phase was extracted by ethylacetate and aqueous sodium chloride solution. Moisture contained in the organic phase was removed by using magnesium sulfate. After filtration, the solvent was evaporated under reduced pressure. The residue was purified by silica gel column chromatography to obtain the title compound 504 mg (yield: 94%).
1H-NMR (300 MHz, CDCl3) δ: 7.23 (m, 5H), 7.08 (m, 2H), 6.92 (d, 1H, J=7.8 Hz), 6.79 (t, 1H, J=15.1 and 7.6 Hz), 6.54 (br s, 1H), 3.84 (br s, 2H).
13C-NMR (75.5 MHz, CDCl3) δ: 157.3, 137.8, 136.6, 132.2, 131.6, 129.4, 128.9, 128.7, 127.6, 122.0, 120.8, 118.4, 116.4, 114.9, 41.6.
The same procedure as described in Example 40 was repeated but 2-bromophenol was replaced with 3-bromophenol 346 mg (2 mmol). After purification, the title compound 338 mg (yield: 78%) was obtained.
1H-NMR (300 MHz, CDCl3) δ: 7.26 (m, 5H), 7.10 (t, 1H, J=16.0 and 8.0 Hz) 6.85 (d, 1H, J=7.8 Hz), 6.77 (t, 1H, J=3.9 and 1.9 Hz), 6.63 (dd, 1H, J=8.1 and 2.4 Hz), 5.46 (br s, 1H), 4.09 (s, 2H).
13C-NMR (75.5 MHz, CDCl3) δ: 155.9, 138.2, 137.4, 130.1, 129.0, 128.7, 127.4, 121.8, 116.2, 113.6, 38.7.
The same procedure as described in Example 40 was repeated but 2-bromophenol was replaced with 4-bromophenol 346 μl (2 mmol). After purification, the title compound 372 mg (yield: 86%) was obtained.
1H-NMR (300 MHz, CDCl3) δ: 7.26˜7.16 (m, 7H), 6.69 (d, 2H, J=8.4 Hz), 5.29 (br s, 1H), 3.97 (s, 2H).
13C-NMR (75.5 MHz, CDCl3) δ: 155.4, 138.2, 134.5, 129.1, 128.6, 127.2, 126.3, 116.1, 41.4.
The same procedure as described in Example 40 was repeated but 2-bromophenol was replaced with 4-bromo-2,6-dimethylphenol 402 mg (2 mmol). After purification, the title compound 303 mg (yield: 62%) was obtained.
1H-NMR (300 MHz, CDCl3) δ: 7.29˜7.21 (m, 7H), 6.90 (s, 1H), 3.98 (s, 2H), 2.18 (s, 6H).
The same procedure as described in Example 40 was repeated but 2-bromophenol was replaced with 4-bromo-2-chlorophenol 415 mg (2 mmol). After purification, the title compound 411 mg (yield: 82%) was obtained.
1H-NMR (300 MHz, CDCl3) δ: 7.28˜7.19 (m, 6H), 7.12 (dd, 1H, J=8.5 and 2.2 Hz), 6.89 (d, 1H, J=8.5 Hz) 5.53 (br s, 1H), 3.99 (s, 2H).
The same procedure as described in Example 40 was repeated but 2-bromophenol was replaced with 4-fluoro-2-bromophenol 382 mg (2 mmol). After purification, the title compound 244 mg (yield: 52%) was obtained.
1H-NMR (300 MHz, CDCl3) δ: 7.25 (m, 3H), 7.08 (m, 2H), 6.97˜6.86 (m, 3H), 6.27 (s, 1H), 3.85 (s, 2H).
The same procedure as described in Example 40 was repeated but 2-bromophenol and benzylbromide were replaced with 2-bromo-4-fluorophenol 382 mg (2 mmol) and 1-bromo-2-pentyne 204 μl (2 mmol, 1.0 equivalent), respectively. After purification, the title compound 374 mg (yield: 89%) was obtained.
1H-NMR (300 MHz, CDCl3) δ: 7.24-7.28 (m, 1H), 6.91-7.04 (m, 2H), 6.56 (s, 1H), 3.40 (t, 2H, J=2.34 Hz), 2.16 (m, 2H), 1.07 (t, 3H, J=7.5 Hz).
13C-NMR (75.5 MHz, CDCl3) δ: 157.99, 154.80, 154.18, 154.15, 122.62, 122.32. 119.02, 118.91, 118.72, 115.97, 115.87, 87.40, 74.67, 25.82, 14.02, 12.82
The same procedure as described in Example 40 was repeated but 2-bromophenol and benzylbromide were replaced with 2-bromo-4-fluorophenol 382 mg (2 mmol) and 5-phenylpentyl bromide 375 μl (2 mmol, 1.0 equivalent), respectively. After purification, the title compound 482 mg (yield: 83%) was obtained.
1H-NMR (300 MHz, CDCl3) δ: 7.11-7.25 (m, 6H), 6.90-6.94 (m, 2H), 6.46 (s, 1H), 2.67 (t, 2H, J=7.27 Hz), 2.56 (t. 2H, J=7.45 Hz), 1.51-1.63 (m, 4H), 1.32-1.43 (m, 2H).
13C-NMR (75.5 MHz, CDCl3) δ: 158.17, 154.98, 153.57, 153.54, 142.71, 128.82, 128.76, 126.20, 121.81, 121.51, 120.49, 120.39, 118.18, 117.88, 115.83, 115.73, 37.01, 36.15, 31.31, 29.92, 28.57
The same procedure as described in Example 40 was repeated but 2-bromophenol and benzylbromide were replaced with 2-bromo-4-fluorophenol 382 mg (2 mmol) and bromomethyl cyclohexane 277 μl (2 mmol, 1.0 equivalent), respectively. After purification, the title compound 389 mg (yield: 81%) was obtained.
1H-NMR (300 MHz, CDCl3) δ: 7.16-7.20 (m, 1H), 6.90-7.00 (m, 2H), 6.50 (s, 1H), 2.64 (d, 2H, J=6.89 Hz), 1.85-1.89 (m, 2H), 1.66-1.77 (m, 3H), 1.46 (m, 1H), 1.17-1.28 (m, 3H), 0.95-0.99 (m, 2H).
13C-NMR (75.5 MHz, CDCl3) δ: 158.15, 154.97, 153.26, 153.23, 121.52, 121.41, 121.30, 121.21, 117.85, 115.75, 115.64, 44.77, 38.09, 32.91, 26.65, 26.31.
The same procedure as described in Example 40 was repeated but 2-bromophenol and benzylbromide were replaced with 4-bromophenol 346 mg (2 mmol) and 2-(2-bromomethyl)-1,3-dioxolan 235 μl (2 mmol, 1.0 equivalent), respectively. After purification, the title compound 353 mg (yield: 78%) was obtained.
1H-NMR (300 MHz, CDCl3) δ: 7.26-7.40 (m, 2H), 6.71-6.77 (m, 2H), 5.60 (br, 1H), 4.97-5.00 (m, 1H), 3.84-4.02 (m, 4H), 2.90 (m, 2H), 1.93 (m, 2H).
13C-NMR (75.5 MHz, CDCl3) δ: 155.60, 134.06, 126.15, 116.47, 103.58, 65.36, 34.04, 30.52.
The same procedure as described in Example 40 was repeated but 2-bromophenol and benzylbromide were replaced with 2-bromo-4-fluorophenol 382 mg (2 mmol) and 1,2-epoxy-5-hexen 228 μl (2 mmol, 1.0 equivalent), respectively. After purification, the title compound 411 mg (yield: 85%) was obtained.
1H-NMR (300 MHz, CDCl3) δ: 7.39 (br, 1H), 7.18-7.22 (m, 1H), 6.89-7.00 (m, 2H), 5.73-5.82 (m, 1H), 4.96-5.05 (m, 2H), 3.70 (br, 1H), 3.05 (br, 1H), 2.93-2.99 (m, 1H), 2.71-2.78 (m, 1H), 2.10-2.20 (m, 2H), 1.58-1.66 (m, 2H).
13C-NMR (75.5 MHz, CDCl3) δ: 158.06, 154.87, 153.88, 153.85, 138.06, 122.16, 121.86, 120.43, 120.32, 118.34, 118.04, 116.73, 116.62, 115.85, 70.02, 44.19, 35.59, 30.3.
The same procedure as described in Example 40 was repeated but 2-bromophenol was replaced with 2-bromobenzylalcohol 374 mg (2 mmol). After purification, the title compound 432 mg (yield: 94%) was obtained.
1H-NMR (300 MHz, CDCl3) δ: 7.15-7.34 (m, 9H), 4.58 (s, 2H), 4.01 (s, 1H), 2.29 (br, 1H).
13C-NMR (75.5 MHz, CDCl3) δ: 142.09, 137.85, 134.51, 132.11, 129.25, 128.98, 128.75, 128.66, 127.97, 127.75, 63.87, 40.24, 31.62.
The same procedure as described in Example 40 was repeated but 2-bromophenol was replaced with 3-bromobenzylalcohol 374 mg (2 mmol). After purification, the title compound 409 mg (yield: 89%) was obtained.
1H-NMR (300 MHz, CDCl3) δ: 7.10-7.26 (m, 9H), 4.54 (s, 2H), 4.09 (s, 2H), 2.05 (br, 1H).
13C-NMR (75.5 MHz, CDCl3) δ: 142.04, 137.75, 137.14, 129.43, 129.31, 129.11, 128.93, 128.43, 127.64, 125.27, 65.28, 39.25.
The same procedure as described in Example 40 was repeated but 2-bromophenol was replaced with 4-bromobenzylalcohol 374 mg (2 mmol). After purification, the title compound 426 mg (yield: 92%) was obtained.
1H-NMR (300 MHz, CDCl3) δ: 7.29-7.20 (m, 9H), 4.60 (s, 2H), 4.09 (s, 2H), 1.87 (br, 1H).
13C-NMR (75.5 MHz, CDCl3) δ: 139.49, 137.80, 135.99, 130.39, 129.22, 128.97, 128.92, 127.92, 127.62, 65.25, 39.4.
The same procedure as described in Example 40 was repeated but 2-bromophenol and benzylbromide were replaced with 4-bromo-benzylalcohol 374 mg (2 mmol) and 1-bromo-2-pentine 204 μl (2 mmol, 1.0 equivalent), respectively. After purification, the title compound 375 mg (yield: 91%) was obtained.
1H-NMR (300 MHz, CDCl3) δ: 7.26-7.42 (m, 4H), 4.63 (s, 2H), 3.59 (m, 2H), 2.16 (m, 1H), 2.02 (br, 1H), 1.08 (t, 3H, J=7.44 Hz).
13C-NMR (75.5 MHz, CDCl3) δ: 139.79, 135.30, 130.49, 127.88, 86.00, 75.25, 65.21, 23.63, 14.22, 12.90.
The same procedure as described in Example 40 was repeated but 2-bromophenol and benzylbromide were replaced with 4-bromo-benzylalcohol 374 mg (2 mmol) and t-butyl bromoacetate 296 μl (2 mmol, 1.0 equivalent), respectively. After purification, the title compound 452 mg (yield: 89%) was obtained.
1H-NMR (300 MHz, CDCl3) δ: 7.23-7.41 (m, 4H), 4.59 (s, 2H), 3.51 (s, 2H), 2.63 (br, 1H), 1.39 (s, 9H).
13C-NMR (75.5 MHz, CDCl3) δ: 169.31, 140.15, 134.65, 130.39, 127.88, 82.41, 64.90, 38.19, 28.27.
The same procedure as described in Example 40 was repeated but 2-bromophenol and benzylbromide were replaced with 4-bromo-benzylalcohol 374 mg (2 mmol) and 2-(2-bromomethyl)-1,3-dioxolan 235 μl (2 mmol, 1.0 equivalent), respectively. After purification, the title compound 360 mg (yield: 75%) was obtained.
1H-NMR (300 MHz, CDCl3) δ: 7.19-7.36 (m, 4H), 4.96 (t, 1H, J=4.46 Hz), 4.60 (s, 2H), 3.81-3.97 (m, 4H) 2.97-3.02 (m, 2H), 2.29 (br, 1H), 1.97 (m, 1H).
13C-NMR (75.5 MHz, CDCl3) δ: 139.22, 135.79, 129.70, 128.02, 103.42, 65.38, 65.14, 33.86, 28.28.
The same procedure as described in Example 40 was repeated but 2-bromophenol and benzylbromide were replaced with 4-bromo-benzylalcohol 374 mg (2 mmol) and 1,2-epoxy-5-hexen 228 μl (2 mmol, 1.0 equivalent), respectively. After purification, the title compound 395 mg (yield: 83%) was obtained.
1H-NMR (300 MHz, CDCl3) δ: 7.22-7.34 (m, 4H), 5.78 (m, 1H), 4.94-5.05 (m, 2H), 4.59 (s, 2H), 3.68 (m, 1H), 3.06-3.12 (m, 1H), 2.81-2.88 (m, 3H), 2.15 (m, 2H), 1.60 (m, 2H).
13C-NMR (75.5 MHz, CDCl3) δ: 139.81, 138.40, 134.91, 130.40, 128.08, 115.45, 69.44, 64.88, 42.39, 35.53, 30.28.
The same procedure as described in Example 40 was repeated but 2-bromophenol was replaced with 2-bromo-phenethylalcohol 402 mg (2 mmol). After purification, the title compound 444 mg (yield: 91%) was obtained.
1H-NMR (300 MHz, CDCl3) δ: 7.13-7.36 (m, 9H), 4.08 (s, 2H), 3.77 (dd, 2H, J=6.66 Hz, 6.69 Hz), 2.96 (dd, 2H, J=6.66 Hz, 6.69 Hz), 1.36 (br, 1H).
13C-NMR (75.5 MHz, CDCl3) δ: 138.85, 137.36, 135.84, 130.56, 130.42, 129.00, 128.64, 127.40, 127.37, 126.74, 62.80, 39.44, 37.32.
The same procedure as described in Example 40 was repeated but 2-bromophenol was replaced with 3-bromo-phenethylalcohol 402 mg (2 mmol). After purification, the title compound 439 mg (yield: 90%) was obtained.
1H-NMR (300 MHz, CDCl3) δ: 7.03-7.28 (m, 9H), 4.10 (s, 2H), 3.79 (m, 2H), 2.78 (t, 2H, J=6.49 Hz), 1.34 (br, 1H).
13C-NMR (75.5 MHz, CDCl3) δ: 139.41, 137.52, 136.55, 130.48, 129.48, 129.10, 128.96, 128.63, 128.56, 127.88, 127.29, 127.24, 63.47, 39.07, 39.00.
The same procedure as described in Example 40 was repeated but 2-bromophenol was replaced with 4-bromo-phenethylalcohol 402 mg (2 mmol). After purification, the title compound 439 mg (yield: 90%) was obtained.
1H-NMR (300 MHz, CDCl3) δ: 7.10-7.28 (m, 9H), 4.09 (s, 2H), 3.83 (m, 2H), 2.82 (t, 2H, J=6.51 Hz), 1.37 (br, 1H).
13C-NMR (75.5 MHz, CDCl3) δ: 137.94, 137.33, 134.58, 130.77, 129.95, 129.22, 128.88, 127.56, 63.91, 39.73, 39.10.
The same procedure as described in Example 40 was repeated but 2-bromophenol was replaced with 6-bromo-2-naphtol 446 mg (2 mmol). After purification, the title compound 490 mg (yield: 92%) was obtained.
1H-NMR (300 MHz, CDCl3) δ: 7.67 (d, 1H, J=1.6 Hz), 7.60 (d, 1H, J=9.3 Hz), 7.55 (d, 1H, J=8.7 Hz), 5.13 (br s, 1H), 4.15 (s, 2H).
13C-NMR (75.5 MHz, CDCl3) δ: 153.7, 137.8, 133.5, 130.9, 129.5, 129.4, 129.1, 128.7, 127.4, 127.1, 118.5, 109.7, 39.9.
The same procedure as described in Example 40 was repeated but 2-bromophenol and benzylbromide were replaced with 4-bromophenol 346 mg (2 mmol) and tert-butyl bromoacetate 295 μl (2 mmol, 1.0 equivalent), respectively. After purification, the title compound 447 mg (yield: 93%) was obtained.
1H-NMR (300 MHz, CDCl3) δ: 7.31 (d, 2H, J=8.8 Hz), 6.67 (d, 2H, J=8.8 Hz), 6.33 (br s, 1H), 3.39 (s, 2H), 1.39 (s, 9H).
4-iodine-2-methyl-phenoxy-tert-butyldimethyl silane 500 mg (1.74 mmol) was completely dissolved in dry tetrahydrofuran 40 ml under nitrogen atmosphere, and the mixture was cooled to −78° C. To the mixture, n-butyl lithium 1.09 ml (1.6M in hexane, 1.0 equivalent) was slowly added for 1 minute. After stirring additional 10 minutes, sulfur powder 55.7 mg (1.74 mmol, 1.0 equivalent) was added at once at the same temperature. After stirring the mixture at the same temperature for additional 10 minutes to completely dissolve sulfur, 5-chloromethyl-4-methyl-2-[(4-trifluoromethyl)phenyl]thiazol 420 mg (1.74 mmol, 1.0 equivalent) was added at once. Reaction was carried out so that the temperature of overall reaction mixture was raised to room temperature in 60 minutes. Aqueous ammonium chloride solution was added thereto to quench the reaction. The organic phase was extracted by using ethyl acetate and aqueous sodium chloride solution. Moisture contained in the organic phase was removed by using magnesium sulfate. After filtration, the solvent was evaporated under reduced pressure. The residue was purified by silica gel column chromatography to obtain the title compound 730 mg (yield: 84.6%).
1H-NMR (300 MHz, CDCl3) δ: 7.97 (d, 2H, J=8.0 Hz), 7.65 (d, 2H, J=8.2 Hz), 7.17 (d, 1H, J=1.8 Hz), 7.07 (dd, 1H, J=8.2 and 2.3 Hz), 6.67 (d, 1H, J=8.3 Hz), 4.10 (s, 2H), 2.20 (s, 3H), 2.15 (s, 3H), 1.00 (s, 9H), 0.20 (s, 6H).
13C-NMR (75.5 MHz, CDCl3) δ: 163.4, 154.9, 151.8, 136.8, 132.6, 130.4, 129.6 (q, J=32 Hz), 126.8, 126.2 (q, J=4 Hz), 125.2, 119.6, 33.0, 26.1, 18.7, 17.1, 15.2,-3.9.
4-iodine-2-methylphenol 11.7 g (50.0 mmol) was completely dissolved in dry tetrahydrofuran 400 ml under nitrogen atmosphere, and the mixture temperature was maintained at 0° C. To the mixture, isopropylmagnesium chloride 27.5 ml (2.0 M-ether, 1.1 equivalent) was slowly added at the same temperature. After 10 minutes, the mixture was cooled to −78° C. tert-Butyl lithium 64.7 μl (1.7 M-pentane, 2.2 equivalent) was slowly added. After 20 minutes, sulfur powder 1.60 g (50 mmol, 1.0 equivalent) dissolved in dry THF 50 ml was slowly added. Reaction was carried out so that the temperature of overall reaction mixture was raised to 0° C. After 60 minutes, 5-chloromethyl-4-methyl-2-[(4-trifluoromethyl)phenyl]thiazol 13.1 g (45.0 mmol, 0.9 equivalent) dissolved in dry THF 40 ml was added at 0° C. After 30 minutes at room temperature, aqueous ammonium chloride solution 500 μl was added thereto to quench the reaction. The organic phase was extracted. Moisture contained in the organic phase was removed by using magnesium sulfate. After filtration, the solvent was evaporated under reduced pressure. The residue was purified by silica gel column chromatography using hexan/ethylacetate (v/v=3/1) to obtain the title compound 16.2 mg (yield: 91%).
1H-NMR (300 MHz, CDCl3) δ: 7.96 (d, 2H, J=8.2 Hz), 7.64 (d, 2H, J=8.3 Hz), 7.20 (d, 1H, J=1.8 Hz), 6.97 (dd, 1H, J=8.2 and 2.2 Hz), 6.59 (d, 1H, J=8.2 Hz), 5.52 (br s, 1H), 4.06 (s, 2H), 2.19 (s, 3H), 2.09 (s, 3H).
13C-NMR (75.5 MHz, CDCl3) δ: 164.1, 155.5, 151.7, 137.4, 136.8, 133.6, 131.9 (q, J=33 Hz), 131.8, 131.6, 126.9, 126.4 (q, J=4 Hz), 125.9, 123.8, 115.7, 33.2, 16.2, 14.8.
As described above, according to the process of the invention, alkyl aryl sulfide derivatives represented by Chemical Formula (III) can be prepared in a simple process with high yield.
Number | Date | Country | Kind |
---|---|---|---|
10-2004-0085011 | Oct 2004 | KR | national |
10-2005-0099926 | Oct 2005 | KR | national |
Filing Document | Filing Date | Country | Kind | 371c Date |
---|---|---|---|---|
PCT/KR05/03528 | 10/21/2005 | WO | 00 | 6/29/2009 |